3-azidobenzyl alcohol | 89937-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-azidobenzyl alcohol
• 英文别名: (3-azidophenyl)methanol
• CAS: 89937-85-9
• 化学式: C₇H₇N₃O
• mdl: MFCD19439657
• 分子量: 149.152
• InChiKey: BBWVHPYOSCPZGJ-UHFFFAOYSA-N

物化性质

• 沸点：
  92 °C(Press: 0.9 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  34.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-azidobenzyl alcohol 在 三溴化磷 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以95%的产率得到1-azido-3-(bromomethyl)benzene
  参考文献：
  名称：

  Synthesis of Photophore and Fluorophore Modified O-Benzylserine Derivatives

  摘要：

  O-Benzylation of serine is one of the important protection methods for solid phase peptide synthesis. The utilities of the protection group may be indicated that chemical modifications for O-benzylserine will be utilized to make functional peptides on solid phase synthesis. Detailed studies for effective synthesis of photoreactive and fluorophore containing O-benzylserine derivatives without racemization were reported.

  DOI：

  10.3987/com-16-s(s)37
• 作为产物：
  描述：

  3-硝基苯甲醇 在 sodium azide 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-azidobenzyl alcohol
  参考文献：
  名称：

  Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin

  摘要：

  A convenient and modular synthesis involving diastereoselective Michael addition followed by regioselective Huisgen 1,3-dipolar cycloaddition reaction was carried out to furnish 1,4-disubstituted-1,2,3-triazoles of Ludartin. This reaction scheme involving Michael addition followed by regioselective Huisgen 1,3-dipolar cycloaddition reaction leading to the formation of triazolyl analogs is being reported for the first time. All the triazolyl products were characterised using spectral data analysis. Sulphorhodamine B cytotoxicity screening of the resulting products against a panel of five human cancerous cell-lines revealed that few of the analogs display promising broad spectrum cytotoxic effect. Among all the synthesized compounds, only 3q displayed the best cytotoxic effect with IC50 values of 12, 11, 38, 39 and 8.5 mu M but less than the standard Ludartin (1) with IC50 values of 6.3, 7.4, 7.5, 6.9 and 0.5 mu M against human neuroblastoma (T98G), lung (A-549), prostate (PC-3), colon (HCT-116) and breast (MCF-7) cancer cell lines, respectively. The present synthesis was designed based on the previous literature reports of Ludartin as an aromatase inhibitor. Our work provides an initial study on structure-activity relationship of triazolyl analogs of sesquiterpene lactones in general and Ludartin (1) in particular. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.018

文献信息

• 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
  申请人：Life & Brain GmbH

  公开号：EP2465859A1

  公开（公告）日：2012-06-20

  The invention relates to derivatives of the general formulae I and II to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts, or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts, or solvates thereof as adenosine receptor antagonists, in particular for the treatment of neurodegenerative disorders, e.g. stroke, amylotrophic lateral sclerosis, dementia, Alzheimer's disease, Parkinson's disease, ischemia/reperfusion injury, inflammation, and/or neurological disorder. The blockade of adenosine receptors could also be useful for other indications regarding the metabolism, e.g. diabetic retinopathy, diabetes mellitus, hyperbaric oxygen-induced retinopathy and/or obesity. Applications could also be the treatment of allergic diseases and autoimmune diseases, including mast cell degranulation, asthma, bronchoconstriction, pulmonary fibrosis, inflammatory or obstructive airways disease and/or chronic obstructive pulmonary disease (COPD). In addition, they could be used to treat cancer, e.g. proliferating tumor, cell proliferation disorders, angiogenesis, lung cancer, breast cancer, pancreatic cancer, thyroid cancer, skin cancer, vascular endothelial cancer, cancer of the central nervous system, esophageal cancer, cancer of the larynx, gastrointestinal cancer, colon cancer, colorectal cancer, rectal cancer, liver cancer, renal cancer, prostate cancer, bladder cancer, cervical cancer, ovarian cancer, endometrial cancer, melanoma, squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer selected from squamous cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquam- ous carcinoma and/or undifferentiated carcinoma. The diseases associated with adenosine receptors are also diabetes, diarrhea, inflammatory bowel disease and/or gastrointestinal tract disorders. Adenosine receptor antagonists could be effective for treating a hepatic disease or condition for reducing fat deposition in the liver or fibrosis of the liver. The use of compounds of general formulae I and II can be associated with many applications e.g., scleroderm arthritis, atherosclerosis, urticaria, myocardial infarction, myocardial reperfusion after ischemia, vasodilation, hypertension, hypersensitivity, myocardial ischemia, heart attack and/or retinopathy of prematurity.

  本发明涉及具有通用公式I和II的衍生物，以及它们的制备方法，包含所述化合物的药物制剂以及/或可以从它们产生的生理上相容的盐或溶剂化物，以及所述化合物、盐或溶剂化物作为腺苷受体拮抗剂的药物用途，特别是用于治疗神经退行性疾病，例如中风、肌萎缩侧索硬化、痴呆、阿尔茨海默病、帕金森病、缺血/再灌注损伤、炎症和/或神经系统疾病。腺苷受体的阻断还可能对其他与代谢有关的适应症有益，例如糖尿病视网膜病变、糖尿病、高氧引起的视网膜病变和/或肥胖。应用还可能是治疗过敏性疾病和自身免疫性疾病，包括肥大细胞脱粒、哮喘、支气管收缩、肺纤维化、炎症性或阻塞性气道疾病和/或慢性阻塞性肺病（COPD）。此外，它们还可用于治疗癌症，例如增殖性肿瘤、细胞增殖障碍、血管生成、肺癌、乳腺癌、胰腺癌、甲状腺癌、皮肤癌、血管内皮癌、中枢神经系统癌症、食管癌、喉癌、胃肠癌、结肠癌、结直肠癌、直肠癌、肝癌、肾癌、前列腺癌、膀胱癌、宫颈癌、卵巢癌、子宫内膜癌、黑色素瘤、鳞状细胞癌、基底细胞癌、非小细胞肺癌（包括鳞状细胞癌、腺癌、大细胞癌、腺鳞癌和/或未分化癌）。与腺苷受体相关的疾病还包括糖尿病、腹泻、炎症性肠病和/或胃肠道的疾病。腺苷受体拮抗剂可能对治疗肝脏疾病或状况有效，用于减少肝脏脂肪沉积或肝脏纤维化。通用公式I和II的化合物的使用可以与许多应用相关，例如，硬皮病关节炎、动脉粥样硬化、荨麻疹、心肌梗死、缺血后心肌再灌注、血管扩张、高血压、过敏反应、心肌缺血、心脏病发作和/或早产儿视网膜病变。
• [EN] 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 8-TRIAZOLYLXANTHINE, LEURS PROCÉDÉS DE FABRICATION ET LEUR UTILISATION EN TANT QU'AGONISTES DE RÉCEPTEURS DE L'ADÉNOSINE
  申请人：LIFE & BRAIN GMBH

  公开号：WO2012076974A1

  公开（公告）日：2012-06-14

  The invention relates to derivatives of the general formulae (I) and (II) to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts or solvates or prodrugs which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as adenosine receptor antagonists, in particular for the treatment of neurodegenerative disorders, e.g. stroke, amylotrophic lateral sclerosis, dementia, Alzheimer's disease, Parkinson's disease, ischemia/reperfusion injury, inflammation, and/or neurological disorder. The blockade of adenosine receptors could also be useful for other indications regarding the metabolism, e.g. diabetic retinopathy, diabetes mellitus, hyperbaric oxygen - induced retinopathy and/or obesity. Applications could also be the treatment of allergic diseases and autoimmune diseases, including mast cell degranulation, asthma, bronchoconstriction, pulmonary fibrosis, inflammatory or obstructive airways disease and/or chronic obstructive pulmonary disease (COPD). In addition, they could be used to treat cancer. The diseases associated with adenosine receptors are also diabetes, diarrhea, inflammatory bowel disease and/or gastrointestinal tract disorders. Adenosine receptor antagonists could be effective for treating a hepatic disease or condition for reducing fat deposition in the liver or fibrosis of the liver. The use of compounds of general formulae I or II can be associated with many applications e.g., scleroderm arthritis, atherosclerosis, urticaria, myocardial infarction, myocardial reperfusion after ischemia, vasodilation, hypertension, hypersensitivity, myocardial ischemia, heart attack and/or retinopathy of prematurity.

  本发明涉及具有通用公式(I)和(II)的衍生物，以及它们的制备方法，含有所述化合物的药物制剂以及/或可以从它们产生的生理上相容的盐或溶剂化物或前药，以及所述化合物、其盐或溶剂化物作为腺苷受体拮抗剂的药物用途，特别是用于治疗神经退行性疾病，例如中风、肌萎缩性侧索硬化症、痴呆、阿尔茨海默病、帕金森病、缺血/再灌注损伤、炎症和/或神经系统疾病。阻断腺苷受体对于涉及代谢的其他适应症也可能有用，例如糖尿病视网膜病变、糖尿病、高氧诱导视网膜病变和/或肥胖。应用还可以包括治疗过敏性疾病和自身免疫性疾病，包括肥大细胞脱粒、哮喘、支气管收缩、肺纤维化、炎症性或阻塞性气道疾病和/或慢性阻塞性肺病（COPD）。此外，它们还可以用于治疗癌症。与腺苷受体相关的疾病还包括糖尿病、腹泻、炎症性肠病和/或胃肠道疾病。腺苷受体拮抗剂可能对治疗肝病或减少肝脏脂肪沉积或肝脏纤维化有效。通用公式I或II的化合物的使用可以与许多应用相关联，例如，硬皮病关节炎、动脉硬化、荨麻疹、心肌梗死、缺血后心肌再灌注、血管舒张、高血压、过敏反应、心肌缺血、心脏病发作和/或早产儿视网膜病变。
• General Copper-Catalyzed Transformations of Functional Groups from Arylboronic Acids in Water
  作者：Haijun Yang、Yong Li、Min Jiang、Junmei Wang、Hua Fu

  DOI：10.1002/chem.201003711

  日期：2011.5.9

  A simple and general copper‐catalyzed method has been developed for transformations of various functional groups (I, N3, SO2R, OH, NH2, and NO2) on aromatic rings from arylboronic acids in water under air. The protocol uses cheap and readily available inorganic salts (KI, NaN3, NaSO2R, NaOH, NaNO2) and aqueous ammonia as the functional‐group sources, simple Cu2O/NH3 as the catalyst system, environmentally

  简单和一般铜催化方法已被开发用于各种官能团的变换（ I， Ñ 3， SO 2 R， OH， NH 2，和 NO 2）从在水中的芳基硼酸的芳环在空气中。该协议使用廉价且容易获得的无机盐（KI，NaN 3，NaSO 2 R，NaOH，NaNO 2）和氨水作为官能团来源，即简单的Cu 2 O / NH 3。作为催化剂体系，环境友好的水作为溶剂，空气中的氧气作为氧化剂。重要的是，水中的铜催化剂体系是可回收的。该研究应为芳香环上官能团的相互转化提供有用的策略。
• Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents
  作者：Rabiya Majeed、Payare L. Sangwan、Praveen K. Chinthakindi、Imran Khan、Nisar A. Dangroo、Niranjan Thota、Abid Hamid、Parduman R. Sharma、Ajit K. Saxena、Surrinder Koul

  DOI：10.1016/j.ejmech.2013.03.028

  日期：2013.5

  carried out on betulinic acid, through concise 1,2,3-triazole synthesis via click chemistry approach at C-3position in ring A have been evaluated for their cytotoxic potentiation against nine human cancer cell lines. Most of the derivatives have shown higher cytotoxic profiles than the parent molecule. Two compounds i.e. 31N(2-cyanophenyl)-1H-1,2,3-triazol-4yl}methyloxy betulinic acid (7) and 31N(5-hyd

  目前，来自自然界的细胞毒性剂是抗癌化学疗法的主要手段，因此迫切需要增强抗癌剂库的需求。已通过在A环C-3位的C-3位置通过单击化学方法通过简明的1,2,3-三唑合成对桦木酸进行的化学转化研究，评估了它们对9种人类癌细胞系的细胞毒性增强作用。大多数衍生物显示出比母体分子更高的细胞毒性谱。两种化合物，即3 1 Ñ（2-氰基苯基）-1 ħ 1,2,3-三唑-4-基}甲氧基桦木酸（7）和3 1 Ñ（5-羟基-萘-1-基）-1 ħ - 1,2,3-三唑-4基}甲氧基苯丁酸（13）对白血病细胞系HL-60表现出令人印象深刻的IC 50值（分别为2.5和3.5μM）（效力比白果酸高5至7倍）。从各种生物学终点来看，证明了对细胞迁移和集落形成的抑制，线粒体膜的破坏，随后的DNA片段化和凋亡。
• Synthesis and biological evaluation of novel 3- O -tethered triazoles of diosgenin as potent antiproliferative agents
  作者：Masood-ur-Rahman、Younis Mohammad、Khalid Majid Fazili、Khursheed Ahmad Bhat、Tabassum Ara

  DOI：10.1016/j.steroids.2016.11.003

  日期：2017.2

  as the most potent analogue against A549 cancer cell line having IC50 of 5.54 &mgr;M, better than the positive control (BEZ‐235). Dgn‐2 and Dgn‐5 bearing o‐nitrophenyl and o‐cyanophenyl R moieties respectively, displayed impressive anti‐proliferative activity against all the tested human cancer cell lines with IC50 values ranging from 5.77 to 9.44 &mgr;M. The structure‐activity relationship (SAR) revealed

  HIGHLIGHTSA 制备了薯蓣皂苷元的三唑衍生物系列。通过MTT 法评估了它们的细胞毒活性。Dgn-1 被鉴定为最有效的抗A549 细胞类似物。摘要薯蓣皂苷元是一种有前景的抗癌甾体皂苷元，是从薯蓣中分离得到的。保持其立体化学丰富的结构完整，使用Cu（I）催化的炔烃-叠氮化物环加成设计合成新型薯蓣皂苷元类似物的方案，以研究它们的构效关系。薯蓣皂苷元及其类似物对四种人类癌细胞系均表现出有趣的抗增殖作用，即。HBL-100（乳房）、A549（肺）、HT-29（结肠）和 HCT-116（结肠）使用 [3-(4,5-二甲基噻唑基-2)-2,5-二苯基溴化四唑] (MTT) 测定。在合成的类似物中，带有通过三唑连接到母体分子的简单苯基 R 部分的 Dgn-1 被鉴定为对抗 A549 癌细胞系最有效的类似物，其 IC50 为 5.54 μM，优于阳性对照 (BEZ-235)。分别带有邻硝基苯基和邻氰基苯基